IPCI -- Hot Stock für 2010 !!!! - 500 Beiträge pro Seite

[BrauchGeld]

Intellipharma ist erst seit mitte Oktober 09 nach der Übernahme von Vasogen an der Nasdaq gelistet .

IPCI wird von eimem Top Team geleitet die schon einige Produkte entwickelt und erfolgreich auf den Markt für Biovail gebracht haben .

Aktuell wartet IPCI auf eine US-Zulassung für eines ihrer Produkte mit hohem Potential und auf final PIII resultat für ein weiteres Produkt .

Das Potential ist gewaltig spätestens wenn die Zulassung das ist wird man es sehen .

Intellipharmaceutics (IPCI)

Marktkap : 26,3 Mio$
Cash : 10 Mio$ ( Cashburn ca. 2 Mio$ pro Jahr )
Kur : 1,56 $

Shares Out : 16,9 M


Pipeline umfasst 15 Produkte ......

Product (Country) Type Status

Product I (USA) ANDA Filed with FDA >> Zulassung kann täglich erfolgen

Product II (USA) ANDA Awaiting results of Pivotal Clinical Studies >> auch bald fällig

Product III (USA) ANDA Scaled-up, Submission batched manufactured; Undergoing stability
studies; Pivotal. bioequivalence studies have commenced

Product IV (USA) ANDA Scaled-up, Submission batched manufactured; Undergoing stability
studies; Pivotal bioequivalence Studies have commenced

Product V (USA) ANDA Scaled-up, Submission batched manufactured; Undergoing stability
studies.

Product VI (USA) ANDA Scaled-up, Submission batched manufactured; Undergoing stability
studies.

Product VII (USA) ANDA Scale up

Product VIII (USA) ANDA Scale Up

Product IX (USA) NDA Production for further Bioavailability Studies

Product X (USA) NDA Bioavailability Studies; Consulting with FDA

Product XI (USA) ANDA Formulation

Product XII (USA) ANDA Formulation

Product XIII (USA) ANDA Formulation

Product XIV (USA) NDA Pre-formulation

Product XV (USA) NDA Pre-formulation

[BrauchGeld]

Antwort auf Beitrag Nr.: 38.653.185 von BrauchGeld am 01.01.10 16:18:44

Allein der CEO hält 6 Mio Aktien !
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…

Insider
http://canadianinsider.com/coReport/allTransactions.php?tick…



Dr. Issa Odidi (CEO)

Dr. Issa Odidi is Founder, Chairman of the Board, Chief Executive Officer, Co-Chief Scientific Officer and Chair of the Scientific Advisory Board of IntelliPharmaCeutics. He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine, California, U.S.A.

Professor Issa Odidi received his B.Sc. degree in Pharmacy, from Ahmadu Bello University in Nigeria, his M.Sc., Pharmaceutical Technology and Ph.D Pharmaceutics degrees from the University of London, England.

Dr. Amina Odidi is a Founder, Director, President, Chief Operating Officer and Co-Chief Scientific Officer of IntelliPharmaCeutics.

Dr. Amina Odidi received her B.Sc. degree in Pharmacy, from Ahmadu Bello University, and her M.Sc., Biopharmaceutics and Ph.D Pharmaceutics degrees from the University of London, England.

The Chief Scientists at IntelliPharmaCeutics, Dr. Issa Odidi and Dr. Amina Odidi, are the inventors of each of the diverse core drug delivery technologies which the company now successfully exploits. They were also directly responsible for the design, development and advancement to production scale of each of the ten FDA-approved and commercially successful drugs and dosage strengths now on sale in the United States.

IntelliPharmaCeutics is a leading edge designer and developer of controlled release drug products. Backed by the Company's breakthrough HYPERMATRIX TM drug delivery technology, its world class team of R&D scientists have enjoyed unprecedented success in developing blockbuster controlled release drugs for their clients.

IntelliPharmaCeutics' track record in designing and developing controlled release drug products for its clients is second to none. Of the approximately 15 bio-equivalent controlled release products in the U.S. market today, 7 of them were designed and developed by the Company's scientists and now enjoy strong sales in the demanding U.S. market.

[BrauchGeld]

Antwort auf Beitrag Nr.: 38.653.222 von BrauchGeld am 01.01.10 16:34:18

Par Pharma (PRX) ist Vermarktungspartner für das bald zugelassene Produkt und Zweitgrösster Aktionär von IPCI .

http://www.blackbusinessprofile.com/business-news/black-busi…

IntelliPharmaCeutics is a privately-held specialty pharmaceutical company that is focused on developing and manufacturing new and generic controlled-release pharmaceutical products using its broadly applicable, proprietary delivery technologies. Currently, IntelliPharmaCeutics has 15 product candidates in its development pipeline several of which are partnered with third-party drug companies. IntelliPharmaCeutics' lead product candidates include Dexmethylphenidate XR, a generic version of the marketed drug Focalin XR(R), which is partnered with Par Pharmaceutical and is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA), and Carvedilol CR, a generic version of the brand name drug Coreg CR, an internal pipeline product now ready for entry into pivotal bioequivalence studies.

IPC's shareholders are expected to own approximately 86% of the outstanding common shares of the combined company and Vasogen's shareholders are expected to own approximately 14% of the outstanding common shares. IPC and Vasogen are currently assessing the appropriate capital structure for the combined company moving forward, which will take into consideration of a number of factors, including input from discussions with NASDAQ and the TSX. Following this assessment, IPC and Vasogen plan to outline their proposal and plans in a joint proxy circular to be provided to shareholders, which is expected to be filed in the coming weeks. Dr. Isa Odidi and Dr. Amina Odidi would together beneficially own approximately 55.3% of the combined company. IPC's second largest shareholder, Par Pharmaceutical, which acquired an equity interest in IPC in 2007 at the same time as it entered into a product commercialization agreement with IPC for the development and commercialization of four product candidates, would effectively own approximately 3.6% of the combined company after closing. The combined company will retain ownership of Vasogen's intellectual property; however, the development focus is expected to be principally on IPC's current product pipeline.

[BrauchGeld]

Antwort auf Beitrag Nr.: 38.653.277 von BrauchGeld am 01.01.10 17:01:20

Dexmethylphenidate XR (Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) ist die Generika-Version von Focalin das in 2008 rund 350 Mio$ umsatz allein in USA erzielt hat .<<< Zulassung steht bevor !

Carvedilol CR (Bluthochdruck) ist die Generika-Version von Coreg CR ,US-Umsatz in 2008 lag bei 300 Mio$ .<<< Final Daten in kürze zu erwarten .


Our lead products in the generic, controlled-release pharmaceutical category are Dexmethylphenidate XR (dexmethylphenidate hydrochloride), a generic version of Focalin XR®, which is an extended-release capsule for the treatment of Attention Deficit Hyperactivity Disorder, and Carvedilol CR (carvedilol phosphate), a generic version of Coreg CR®, which is an extended release capsule for the treatment of high blood pressure. In 2008, Focalin®, including Focalin XR®, had U.S. sales of approximately U.S. $350 million, and Coreg®, including Coreg CR®, had U.S. sales of approximately U.S. $300M million.

One of our key non-generic products is an abuse- and alcohol-resistant, controlled-release oral oxycodone formulation. This product is covered by pending patent applications for its novel ReXista(TM) abuse- and alcohol-resistant drug delivery technology. The product is a unique dosage form, designed to be resistant to abuse by oral ingestion when crushed or chewed, by injection when combined with solvents, and by nasal inhalation when crushed or powdered. The abuse of this important pain relief drug has been well documented over many years. In 2008, Oxycodone had U.S. sales of approximately U.S. $2 billion. The product is also designed to resist release of the entire dose when consumed with alcohol, a significant problem with some opioid drugs, such as hydromorphone.








Boden scheint bei 1,40$(Allzeittief) gefunden zu sein ..

[BrauchGeld]

Ausverkauf ist vorbei bald sehen wir neue Höchststände

[BrauchGeld]

Top-Aktie zum Spottpreis ....

[BrauchGeld]

Ich denke 3$ werden wir schnell sehen ....

[BrauchGeld]

Par Pharma könnte eventuell IPCI schlucken immerhin ist die Aktie verdammt billig .

[BrauchGeld]

Höchstes Volumen seit listing ,das sieht gut aus für die nächsten Tage !!!!

[BrauchGeld]

Sieht wieder nach einem guten start aus .....

[BrauchGeld]

Gleich sind wir bei 3$ . Marktkap immer noch bei lächerlichen 42 Mio$ !

[ericcartman]

Hallo, ich brauche auch Geld. Bin mal mit ner kleinen Posi dabei.

[BrauchGeld]

Beim ersten mal hab ich die Gewinne mitgenommen diesmal bleibe ich dabei.Bin froh wieder unter 2$ welche zu bekommen .

US-Zulassung ist auch hier so sicher wie bei Cipher Pharma nur eine Frage der Zeit (spätestens ende 2Q 2010) ...

http://seekingalpha.com/article/187519-some-small-cap-biotec…

Finally, we're hearing chatter that a big fund took a big position in Intellipharmaceutics (IPCI) yesterday. the company has been on a road show and attracting some attention. We're going to try to find out why that is and perhaps arrange an interview with the management team for a future special report.

These funds don't take big positions in the open market like this unless they hear or see something they really like and believe in long-term. Based in Toronto, Ontario, but trading on the Nasdaq, the company reportedly has an impressive and unique drug delivery platform and they are known as a pharmaceutical innovator. Those controlled-release drug delivery technologies are being applied to the development of a wide range of pharmaceuticals. The Company itself has a pipeline of both generic and new drugs.

[BrauchGeld]

Unter 2$ ist IPCI ein Topkauf das sich garantiert lohnen wird ...

[BrauchGeld]

Leicht verdientes geld

[dottore]

Antwort auf Beitrag Nr.: 38.677.352 von BrauchGeld am 06.01.10 18:11:08

man sollte vielleicht deutlich machen, dass die Firma ein Patent hält um Generika, also Nachahmermedikamente in ihrer patentierten Galenik für retardierte Freisetzung des Medikaments besitzt, nicht aber eigene Medikamente entwickelt.
So gesehen ist ein Kurs über 2 $ Wunschdenken und erst langfristig 2011-2012 zu erwarten. Schließlich gibt es jede Menge patentierter Retardierungsgaleniken .....

[BrauchGeld]

Du hälst wohl das Patent für Dummgeschwätz ...


Das einizige Problem hier ist das IPCI kaum einer kennt sonst gar nichts .....

[BrauchGeld]

Hab heute 6000st gekauft und besitze damit jetzt 15t .IPCI wird auch eine Aktie sein auf die die Amis abfahren werden .

Ich sage nur Strong Buy !

Intellipharma (IPCI)
Marktkap: 35 Mio$
Cash: 8 Mio$
Kurs: 1,55 $

Shares Out : 22 M

Lesen um das Potential zu erkenen !!!!
http://files.shareholder.com/downloads/ABEA-43EQSZ/862481029…

Intellipharmaceutics' development milestones for 2010 include the following:

-- Potential conclusion of the ongoing litigation process and/or FDA approval of Focalin XR

-- File and have accepted for review by the FDA, two additional ANDA applications

-- Establish at least one additional development/marketing alliance

-- Complete successful manufacturing of clinical batches of Rexista(TM)

-- Complete Phase 1 studies using clinical batches of Rexista(TM)

-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical development plan" target="_blank" rel="nofollow ugc noopener">http://files.shareholder.com/downloads/ABEA-43EQSZ/862481029…

Intellipharmaceutics' development milestones for 2010 include the following:

-- Potential conclusion of the ongoing litigation process and/or FDA approval of Focalin XR

-- File and have accepted for review by the FDA, two additional ANDA applications

-- Establish at least one additional development/marketing alliance

-- Complete successful manufacturing of clinical batches of Rexista(TM)

-- Complete Phase 1 studies using clinical batches of Rexista(TM)

-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical development plan

[BrauchGeld]

Dieser link müsste funktionieren .
http://files.shareholder.com/downloads/ABEA-43EQSZ/862481029…

[truberdixx]

Antwort auf Beitrag Nr.: 39.088.757 von BrauchGeld am 08.03.10 22:28:27

Hi Brauchgeld,

bin hier auch schon seit paar Wochen investiert. Bis Ende des Jahres müsste da einiges drin sein.

Bist du eigentlich noch in Cipher investiert? Wie beurteilst du da den Verlauf?

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.092.128 von truberdixx am 09.03.10 12:29:27

KORREKTUR :

AKTIENANZAHL BETRÄGT NUR 10,9 MILLION UND NICHT 22 MILLION !!!


Damit beträgt die Marktkap nur lächerliche 17 Million $ aus diesem grund hab ich gleich nochmal 8t Aktien gekauft und mutiert damit zu einem Schwergewicht in meinem Depot .


http://files.shareholder.com/downloads/ABEA-43EQSZ/865020512…

OUTSTANDING SHARE INFORMATION
The number of shares outstanding as of February 26, 2010, is 10.9 million and it has not changed since November 30, 2009. The number of options outstanding as of February 26, 2010, is 2,929,502 and has decreased since November 30, 2009 due to the expiry of 9,686stock options. No stock options were granted or forfeited since November 30, 2009.

[BrauchGeld]

Die Aktie ist sowas von billig das es schon weh tut ...

IntelliPharmaceutics (IPCI)

Marktkap: 17 Mio$
Cash: 8 Mio$
Kurs: 1,54 $

Shares Out: 22 M

Präsentation März 2010
http://files.shareholder.com/downloads/ABEA-43EQSZ/862519311…



Intellipharmaceutics' development milestones for 2010 include the following:

-- Potential conclusion of the ongoing litigation process and/or FDA
approval of Focalin XR

-- File and have accepted for review by the FDA, two additional ANDA applications

-- Establish at least one additional development/marketing alliance

-- Complete successful manufacturing of clinical batches of Rexista(TM)

-- Complete Phase 1 studies using clinical batches of Rexista(TM)

-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical
development plan

[BrauchGeld]

OH DANKE GOTT DAS DU SO GNÄDIG ZU MIR BIST ..RALLY WIRD STARTEN JETZT NACHDEM ICH VOLLGELADEN BIN

NACHBÖRSLICH GINGS SCHON 15% RAUF .


Intellipharmaceutics Announces Settlement for its Generic Version of Focalin XR(R)

TORONTO, March 11, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride). The terms of the settlements are confidential and remain subject to regulatory and court approval.

[BrauchGeld]

Nur ganz ganz wenige haben begriffen das die News super ist und das IPCI verdammt billig ist .

[BrauchGeld]

Na endlich

[ericcartman]

aber Hallo, der Laden war nahe an meiner Bad Bank

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.127.710 von ericcartman am 12.03.10 18:25:35

Diese Aktie hat wirklich gigantisches Potential würde mich nicht wundern wenn die mal über 10$ steigen würde ..

Marktkap von aktuell nur 21 Mio$ ist für so eine super Pipeline schon fast ein verbrechen .

[BrauchGeld]

RAAALLLLLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY

Bald sehen wir die 5$++ woooohooooooo

[BrauchGeld]

Ich werd verrückt und die Aktie ist immer noch sehrrrrrr weit von der fairen bewertung entfernt GEILLLLLLLLLLLLLLLLl

[BrauchGeld]

[BrauchGeld]

Ich braucvhe den RAllY Affen

[BrauchGeld]

Allein der CEO hält 6 Mio Aktien von den 10,9 M ..

IPCI ist über 3$

[BrauchGeld]

140% aktuell mir wird schon schwindelig

[BrauchGeld]

4$ ich krieg n orgasmus

[BrauchGeld]

Bereitet euch schon mal auf die 5$ vor ...

[BrauchGeld]

nur noch 6 cent entfernt..

[BrauchGeld]

Hab mein kompletten bestand bei run 4,60$ und bin wieder diesmal nur mit 5t bei 4$ eingestiegen ..OOOOOOOOOYEARRRRRR

[BrauchGeld]

verkauft

[HuntingParty]

Antwort auf Beitrag Nr.: 39.130.219 von BrauchGeld am 12.03.10 21:58:38

Hab mich die letzten Tage noch über die ganzen Teilausführungen beim Kauf geärgert. Aber bei dem gigantischen Gewinn kann man jetzt drüber hinwegsehen.

Vielen Dank für Deine Recherche.

[ericcartman]

Komme gerade Heim


Jaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

[larsuwe]

Hallo ! Super gelaufen,denke es wird am Montag wieder in Richtung 3$ laufen.Da Gewinne mitgenommen werden.Ciao Lars! Oder was ist eure Meinung?

[ericcartman]

Die Taxe in Deutschland ist eine reine Frechheit.

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.139.142 von ericcartman am 15.03.10 11:38:34

Einfach umwandeln lassen dann juckt D auch keinen mehr ..

[dottore]

Antwort auf Beitrag Nr.: 39.006.020 von BrauchGeld am 24.02.10 21:00:58

nein, ich halte es nicht für Dummgeschwätz oder so was, ich bin nur weniger euphorisch. Glaube auch, dass der Wert wieder in Stufen fallen wird.

Kompliment im Nachhinein für dein Timing!

[BrauchGeld]

Knapp 33 Mio$ Marktkapitalisierung ist definitiv zu wenig ...

The Long And Short Of Intellipharmaceutics International
3/15/2010 5:59 AM ET

http://www.rttnews.com/Content/CanadianNews.aspx?Node=B1&Id=…

[BrauchGeld]

Man konnte in den letzten Wochen ziemlich billig einsteigen das habe ich auch genutzt und hab auf rund 2,70 $ verbilligt .

US Zulassung kommt kann sich nur noch um wenige Tage handeln ....

[zpo]

.

Geht was

.

[zpo]

.

+ 34 %

.

[zpo]

.

TORONTO, June 14, 2010 (GLOBE NEWSWIRE)

Itellipharmaceutics International Inc. (Nasdaq:IPCI - News) (TSX:I - News) today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix(R) (delayed release pantoprazole sodium).

Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.

Sales of pantoprazole sodium delayed-release tablets in the United States were approximately $1.8 billion in 2009. Pantoprazole delayed-release tablets is the fourth ANDA product candidate that Intellipharmaceutics has disclosed from its 15 product pipeline, which includes both ANDA product candidates and the development of new drugs through the S.505(b)(2) New Drug Application (NDA) regulatory pathway.

"I am extremely pleased with the progress we continue to make with the advancement of our product pipeline," commented Dr. Isa Odidi, CEO of Intellipharmaceutics. "Protonix is the second ANDA we have filed with the FDA this year and, together with Focalin XR and Effexor XR, it represents another potential source of future revenue from our Company's ANDA pipeline."

...

.

[zpo]

.

erneut im Plus

.

[Growth2012]

Antwort auf Beitrag Nr.: 39.685.897 von zpo am 15.06.10 18:03:32

Guten Abend, hört sich echt nicht schlecht an...

IntelliPharmaCeutics: CEO Speaks of Multiple Deals, FDA Catalysts in the Works

http://seekingalpha.com/article/265305-intellipharmaceutics-…

[Growth2012]

Antwort auf Beitrag Nr.: 41.413.967 von Growth2012 am 26.04.11 22:05:16

Wahrlich beeindrückend...

[Biohero]

IPCI ist und bleibt eines meiner lieblingsaktien nachdem ich bei knapp 5$ alles verhöckert habe bin ich wieder bei rund 3,35$ wieder eingestiegen .

IPCI hat bereits für 5 Produkte die Zulassung bei der FDA beantragt .CEO hat kürzlich erwähnt das einige Partnerschaften für dieses Jahr anstehen und auch eventuell 1-2 FDA Zulassungen .

IPCI und IGXT sind meine absoluten Topfavoriten für 2011 .

Marktkap : 53 M$
Cash: 8.5 M$

http://www.pharmacychoice.com/News/article.cfm?Article_ID=71…

BioMedReports: Dr. Odidi, we’ve been hearing rumors that your company is very close to announcing partnership or licensing deals for some of those drugs. Can you discuss that at all?

CEO, Dr. Isa Odidi: We expect some licensing deals to be announced as well. The licensing deals might be two pronged, 1st to license one or more of the products we have currently in front of the FDA to be marketing to the US and rest of the world and secondly to piggyback on that- a co- development program with one big pharmaceutical player. That is what is happening. Obviously we are also gearing up to manufacture these products cause we expect these products to get into to market after approval- at least the Focalin XR, so we’re gearing up and we are preparing space and equipment to make sure the products can be manufactured when the approvals come. Quite a lot is happening.


BioMedReports: When do you think we might start seeing some of those licensing or partnership deals announced?

CEO, Dr. Isa Odidi: While I can't put a date and time to it, I can tell you that we are working as aggressively as we can and are hopping this is going to happen in the very near term.


BiomedReports: What are your biggest challenges that you see for IPCI?

CEO, Dr. Isa Odidi: I don’t see challenges, I look at it as a puzzle that you have to solve. It’s an issue of managing the change. We are growing rapidly and we have to be able to manage the change carefully. Given the resources we have and the fact that we think we can get to profitability next year, when we start selling Focalin XR. We have to manage change. We are at the point where we are ready to expand manufacturing given that we have 5 products (filed) with the FDA and many more to come. Also, we’re looking to expand the areas of Marketing and Commercialization. So far we have been able to manage all of that.






While serving as Biovail’s Vice President of Research of Drug Development and New Technologies he helped grow Biovail into a multi-billion dollar company. Now he’s doing it all over again, this time with his own emerging biotech-- and many see it as extremely undervalued, given the events which are set to transpire there. That sentiment is underscored by the fact that the company is close to FDA approval and plans immediate commercialization of those drug candidates.



..........................

IPCI: Now has five ANDAs awaiting FDA approval


Intellipharmaceutics (Nasdaq:IPCI), one of the biotech companies whose future as both a near and long-term and investment we've been covering and following closely, today announced the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic of Seroquel XR®.

Seroquel XR® is an oral psychotropic agent indicated for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Sales of Seroquel XR® (quetiapine fumarate extended-release tablets) in the U.S. were approximately $823 million in 2010.

We expect the shares of this very low-float stock will move on this news alone, much less with news about any of the five ANDAs awaiting FDA approval. The reported sales for branded and generic versions of those pending approval products came in at approximately $8 billion in 2010. IPCI develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.

"The filing of a generic version of Seroquel XR® is one of the Company's performance milestones for 2011 and another important addition to our product portfolio filed for approval with the FDA, which includes generics of Focalin XR®, Effexor XR®, Protonix® DR and Glucophage® XR," commented Dr. Isa Odidi, CEO of Intellipharmaceutics. "These filings not only provide further validation of our Hypermatrix™ technology, they clearly demonstrate the flexibility of our technology to efficiently and effectively match a number of drug delivery profiles."

Intellipharmaceutics now has five ANDAs awaiting FDA approval with reported sales for branded and generic versions of these products being approximately $8 billion in 2010. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.

[Biohero]

IPCI bietet immer noch eine günstige Einstiegschance ...

http://biotuesdays.com/2011/06/24/ladenburg-starts-intelliph…

[Biohero]

Mit etwas glück könnten wir heute die 4 dollar marke knacken ....

[Biohero]

Die allererste FDA Zulassung für IPCI steht unmittelbar bevor und ich rechne mit inem heftigen kursgewinn . Warum ? Ganz einfach von den 15.7 Million ausenstehende Aktienanzahl sind 13 Million in festen Händen sowas nennt man Low Float und wenn eine gute Nachricht wie FDA Zulassungen kommt dann explodieren solche Aktien erst recht wenn das Float so brutal niedrig ist wie bei IPCI .

Langfristig (3-5 Jahre ) sehe ich hier kurse von locker 50$+ falls IPCI vorher nicht aufgekauft wird .Marktkap von 59 Million $ ist ein Riesiger Joke für dieses Super Unternehmen .


The FDA’s recent inspection of Focalin manufacturing facilities suggests that the product’s clearance could be
imminent. IPCI aims to file two more ANDAs during the year, establish another strategic alliance covering a
pipeline product, and secure FDA agreement on a clinical development plan for Rexista. These FY2011
developments could lend significant support to the stock’s valuation.


Hier ist eine schöne analyse von Taglich Bros von 13. Juli 2011

http://www.google.de/url?sa=t&source=web&cd=1&ved=0CBoQFjAA&…



5 Produkte sind under review by FDA ..Nicht vergessen der CEO und Besitzer von IPCI hat bereits einige Blockbuster für andere Pharmas auf den Markt gebracht .

[Biohero]

Hab die Pipeline dazu vergessen